



June 7, 2006

Encision Receives Technology Product of the Year Award

Boulder, Colorado, June 7, 2006 -- Encision Inc. (Amex: ECI), a medical device company with patented surgical technology emerging as a standard of care in minimally-invasive surgery, announced that it was the recipient of the CSIA Apex Award for Technology Product of the Year. Jack Serino, President & CEO of Encision, accepted the award Tuesday evening, June 6, during the "Spotlight on Innovation" ceremonies held at the Robert & Judi Newman Center for the Performing Arts at the University of Denver.

"We are pleased that Encision's active electrode monitoring technology has been recognized by the panel of 60 judges who evaluated the many device, information and software technologies of Colorado companies," said Jack Serino.

CSIA is the leading trade association representing the technology industry in Colorado, providing connections, insight and competitive edge programs and services, assisting more than 3,000 Colorado technology companies to succeed and prosper. The mission of CSIA is to foster innovation and a positive growth environment to enable the technology industry in Colorado to compete on a global basis.

Encision Inc. designs and manufactures innovative surgical devices that allow the surgeon to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase revenues through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.

CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.com

###